<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01453036</url>
  </required_header>
  <id_info>
    <org_study_id>CUK</org_study_id>
    <nct_id>NCT01453036</nct_id>
  </id_info>
  <brief_title>Clarithromycin Resistant Tailored Therapy</brief_title>
  <official_title>Eradication of Helicobacter Pylori According to 23S rRNA Point Mutations Associated With Clarithromycin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jin Il Kim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korean College of Helicobacter and Upper Gastrointestinal Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Catholic University of Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Back ground Antibiotics resistance of Helicobacter pylori, especially to clarithromycin
           is one of the main causes of failure of eradication. 23S rRNA point mutation of
           Helicobacter pylori is associated clarithromycin resistance

        2. Hypothesis If the investigators check the 23S rRNA point mutation then choose treatment
           regimens containing a proton pump inhibitor and combination of two antibiotics
           (amoxicillin and clarithromycin or metronidazole), the investigators will eradicate
           Helicoabacter pylori more successfully

        3. Material &amp; methods The investigators enroll patients diagnosed with peptic ulcer,
           endoscopically. Helicobacter pylori is documented with Urea breath test or silver
           staining biopsy specimen or polymerase chain reaction of biopsy specimen. Check the 23S
           rRNA A2142G/A2143G point mutation by polymerase chain reaction. If there is mutation,
           the investigators consider as resistance to clarithromycin and choose the treatment
           regimen containing a proton pump inhibitor, amoxicillin, metronidazole. If there is no
           mutation, choose the treatment regimen containing a proton pump inhibitor, amoxicillin,
           clarithromycin. Verify Helicobacter pylori eradication by urea breath test. Compare
           eradication rate with conventional treatment,proton pump inhibitor, amoxicillin,
           clarithromycin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Helicobacter Pylori Eradication Rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>Eradication was determined by the C13-urea breath test 6 to 8 weeks after the eradication therapy when PPIs had not been used for at least 2 weeks.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">924</enrollment>
  <condition>Peptic Ulcer</condition>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Conventional AOC group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The investigators do not perform mutation test in the conventional group apply amoxicillin 1 g, bid , rabeprazole 20 mg bid, clarithromycin 500 mg bid during 1weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mutation test group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mutation test group is composed of two groups, clarithromycin group and metronidazole group Clarithromycin subgroup ; no point mutation at 23S rRNA apply clarithromycin 500 mg bid, amoxicillin 1 g bid, rabeprazole 20 mg bid during 1 week Metronidazole subgroup ; point mutation at 23S rRNA apply metronidazole 500 mg tid, amoxicillin 1 g bid, rabeprazole 20 mg bid during 1 week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional AOM group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The investigators do not perform mutation test in the conventional group apply metronidazole 500 mg tid, amoxicillin 1 g bid, rabeprazole 20 mg bid during 1 week</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>23S rRNA point mutation test of Helicobacter pylori</intervention_name>
    <description>mutation test group&gt;&gt; Helicobacter pylori polymerase chain reaction kit by dual-priming oligonucleotide-based multiplex polymerase chain reaction system before eradication of Helicobacter pylori at mutation test groupConventional Conventional AOC group, Conventional AOM group &gt;&gt; no intervention</description>
    <arm_group_label>Mutation test group</arm_group_label>
    <other_name>Seeplex ClaR-Helicobacter pylori polymerase chain reaction kit of Seegene Incorporated, Seoul, Korea</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>UBT test &amp; Gastroenterology with biopsy c silver stain</intervention_name>
    <description>UBT test &amp; Gastroenterology with biopsy c silver stain due to indentify H. pylori infection Conventional AOM group, Conventional AOC group, Mutation test group &gt;&gt; intervention</description>
    <arm_group_label>Conventional AOC group</arm_group_label>
    <arm_group_label>Mutation test group</arm_group_label>
    <arm_group_label>Conventional AOM group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20 - 75 years old

          -  Peptic ulcer (gastric ulcer, duodenal ulcer)

          -  Helicobacter pylori positive

        Exclusion Criteria:

          -  Major comorbidities

          -  Pregnancy

          -  History of Helicobacter pylori eradication

          -  History of gastric surgery or other cancers, except to endoscopic treatment due to
             gastric lesion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyun Jeong Lee, fellow</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yeouido St. Mary's Hospital, The Catholic University of Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dae Young Cheung, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yeouido St. Mary's Hospital, The Catholic University of Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seong Su Kim, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Byeong Ug Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tae Ho Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eun Jung Jeon</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jung Hwan Oh, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Woo Chul Chung, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Soo Heon Park</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jea Kwang Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jin Il Kim</last_name>
    <role>Study Chair</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gastroenterology Clinic</name>
      <address>
        <city>Seoul</city>
        <state>Yeouido-dong/Yeongdeungpo-gu</state>
        <zip>150-713</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Cho DK, Park SY, Kee WJ, Lee JH, Ki HS, Yoon KW, Cho SB, Lee WS, Joo YE, Kim HS, Choi SK, Rew JS. [The trend of eradication rate of Helicobacter pylori infection and clinical factors that affect the eradication of first-line therapy]. Korean J Gastroenterol. 2010 Jun;55(6):368-75. doi: 201006254. Korean.</citation>
    <PMID>20571304</PMID>
  </results_reference>
  <results_reference>
    <citation>Bang SY, Han DS, Eun CS, Kim JE, Ahn SB, Sohn JH, Jeon YC, Kang JO. [Changing patterns of antibiotic resistance of Helicobacter pylori in patients with peptic ulcer disease]. Korean J Gastroenterol. 2007 Dec;50(6):356-62. Korean.</citation>
    <PMID>18159172</PMID>
  </results_reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2011</study_first_submitted>
  <study_first_submitted_qc>October 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2011</study_first_posted>
  <results_first_submitted>June 7, 2012</results_first_submitted>
  <results_first_submitted_qc>July 31, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 27, 2013</results_first_posted>
  <last_update_submitted>July 31, 2013</last_update_submitted>
  <last_update_submitted_qc>July 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Catholic University of Korea</investigator_affiliation>
    <investigator_full_name>Jin Il Kim</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Peptic ulcer</keyword>
  <keyword>Helicobacter pylori</keyword>
  <keyword>Clarithromycin</keyword>
  <keyword>23S rRNA</keyword>
  <keyword>Resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peptic Ulcer</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>five hospitals affiliated with the Catholic University who visited from August 2011 to June 2012</recruitment_details>
      <pre_assignment_details>Mutation test group ; Patients which are no detection of H. pyloriare were excluded</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Conventional AOC Group</title>
          <description>The investigators do not perform mutation test in the conventional group apply amoxicillin 1 g, bid , rabeprazole 20 mg bid, clarithromycin 500 mg bid during 1weeks</description>
        </group>
        <group group_id="P2">
          <title>Mutation Test Group</title>
          <description>Mutation test group is composed of two groups, clarithromycin group and metronidazole group Clarithromycin subgroup ; no point mutation at 23S rRNA apply clarithromycin 500 mg bid, amoxicillin 1 g bid, rabeprazole 20 mg bid during 1 week Metronidazole subgroup ; point mutation at 23S rRNA apply metronidazole 500 mg tid, amoxicillin 1 g bid, rabeprazole 20 mg bid during 1 week</description>
        </group>
        <group group_id="P3">
          <title>Convential AOM Group</title>
          <description>The investigators do not perform mutation test in the conventional group apply metronidazole 500 mg tid, amoxicillin 1 g bid, rabeprazole 20 mg bid during 1 week</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="308"/>
                <participants group_id="P2" count="308"/>
                <participants group_id="P3" count="308"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="282"/>
                <participants group_id="P2" count="193"/>
                <participants group_id="P3" count="277"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="115"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="115"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Convential AOC Group</title>
          <description>amoxicillin 1 g, bid , rabeprazole 20 mg bid, clarithromycin 500 mg bid during 1weeks</description>
        </group>
        <group group_id="B2">
          <title>Mutation Test Group</title>
          <description>Mutation test group is composed of two groups, clarithromycin group and metronidazole group Clarithromycin subgroup ; no point mutation at 23S rRNA apply clarithromycin 500 mg bid, amoxicillin 1 g bid, rabeprazole 20 mg bid during 1 week Metronidazole subgroup ; point mutation at 23S rRNA apply metronidazole 500 mg tid, amoxicillin 1 g bid, rabeprazole 20 mg bid during 1 week</description>
        </group>
        <group group_id="B3">
          <title>Convential AOM Group</title>
          <description>The investigators do not perform mutation test in the conventional group apply amoxicillin 1 g, bid , rabeprazole 20 mg bid, metronidazole 500mg tid during 1weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="308"/>
            <count group_id="B2" value="218"/>
            <count group_id="B3" value="308"/>
            <count group_id="B4" value="834"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="308"/>
                    <measurement group_id="B2" value="218"/>
                    <measurement group_id="B3" value="308"/>
                    <measurement group_id="B4" value="834"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.0" spread="12.0"/>
                    <measurement group_id="B2" value="54.7" spread="12.2"/>
                    <measurement group_id="B3" value="56.2" spread="13.2"/>
                    <measurement group_id="B4" value="54.9" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="205"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="150"/>
                    <measurement group_id="B4" value="404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="158"/>
                    <measurement group_id="B4" value="430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="308"/>
                    <measurement group_id="B2" value="218"/>
                    <measurement group_id="B3" value="308"/>
                    <measurement group_id="B4" value="834"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Helicobacter Pylori Eradication Rate</title>
        <description>Eradication was determined by the C13-urea breath test 6 to 8 weeks after the eradication therapy when PPIs had not been used for at least 2 weeks.</description>
        <time_frame>8 weeks</time_frame>
        <population>Each convential AOC, AOM group : 308 patients Mutation test gorup : H. pylori was not detected by PCR 90 patient , total 218 patient predicted prevalence – 50%, expected dropout rate -15%, predicted eradication rate – 80%, significance level - 0.05, statistical power - 90%</population>
        <group_list>
          <group group_id="O1">
            <title>Convential AOC Group</title>
            <description>amoxicillin 1 g, bid , rabeprazole 20 mg bid, clarithromycin 500 mg bid during 1weeks</description>
          </group>
          <group group_id="O2">
            <title>Mutation Test Group</title>
            <description>Mutation test group is composed of two groups, clarithromycin group and metronidazole group Clarithromycin subgroup ; no point mutation at 23S rRNA apply clarithromycin 500 mg bid, amoxicillin 1 g bid, rabeprazole 20 mg bid during 1 week Metronidazole subgroup ; point mutation at 23S rRNA apply metronidazole 500 mg tid, amoxicillin 1 g bid, rabeprazole 20 mg bid during 1 week</description>
          </group>
          <group group_id="O3">
            <title>Convential AOM Group</title>
            <description>The investigators do not perform mutation test in the conventional group apply amoxicillin 1 g, bid , rabeprazole 20 mg bid, metronidazole 500mg tid during 1weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Helicobacter Pylori Eradication Rate</title>
          <description>Eradication was determined by the C13-urea breath test 6 to 8 weeks after the eradication therapy when PPIs had not been used for at least 2 weeks.</description>
          <population>Each convential AOC, AOM group : 308 patients Mutation test gorup : H. pylori was not detected by PCR 90 patient , total 218 patient predicted prevalence – 50%, expected dropout rate -15%, predicted eradication rate – 80%, significance level - 0.05, statistical power - 90%</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="308"/>
                <count group_id="O2" value="218"/>
                <count group_id="O3" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.9" lower_limit="70.2" upper_limit="81.6"/>
                    <measurement group_id="O2" value="91.2" lower_limit="88.9" upper_limit="93.4"/>
                    <measurement group_id="O3" value="79.1" lower_limit="73.7" upper_limit="84.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Convential AOC Group</title>
          <description>amoxicillin 1 g, bid , rabeprazole 20 mg bid, clarithromycin 500 mg bid during 1weeks</description>
        </group>
        <group group_id="E2">
          <title>Convential AOM Group</title>
        </group>
        <group group_id="E3">
          <title>Mutation Test Group</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jin Il Kim</name_or_title>
      <organization>The Catholic University of Korea</organization>
      <phone>+82-2-3779-2382</phone>
      <email>jikim@catholic.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

